Verrica Pharmaceuticals Inc. Common Stock (VRCA) Stock Price

VRCAStock

$3.60−15.01%52W

Market Cap$61.76M

P/E—

PEG Ratio—

Div yield—

Beta1.67

VRCA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-47.06%

Price vs S&P 500 (4W)-18.61%

VGM Score48.05

Book Value / Share (Quarterly)$0.25

P/TBV (Annual)3.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)57.94%

Cash Flow / Share (Quarterly)$-0.78

Price vs S&P 500 (YTD)-68.67%

Gross Margin (TTM)85.89%

Net Profit Margin (TTM)-102.84%

EPS (TTM)$-1.67

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-1.67

EPS (Annual)$-1.68

ROI (Annual)-69.35%

Gross Margin (Annual)90.33%

Net Profit Margin (5Y Avg)-586.69%

Cash / Share (Quarterly)$0.65

Revenue Growth QoQ (YoY)-53.85%

ROA (Last FY)-37.95%

Revenue Growth TTM (YoY)106.21%

EBITD / Share (TTM)$-1.78

ROE (5Y Avg)-141.89%

Operating Margin (TTM)-98.64%

Cash Flow / Share (Annual)$-1.03

P/B Ratio14.34x

P/B Ratio (Quarterly)24.41x

Net Income / Employee (Annual)$-235,300

EV / Revenue (TTM)1.71x

Net Interest Coverage (TTM)-3.29x

ROA (TTM)-76.60%

EPS Incl Extra (Annual)$-1.68

Current Ratio (Annual)2.59x

Quick Ratio (Quarterly)1.22x

3-Month Avg Trading Volume0.06M

52-Week Price Return-15.01%

Revenue / Employee (TTM)$399,000

Tangible BV / Share (Quarterly)$1.01

P/S Ratio (Annual)1.74x

Asset Turnover (Annual)0.75x

52-Week High$9.82

Operating Margin (5Y Avg)-540.49%

EPS Excl Extra (Annual)$-1.68

CapEx CAGR (5Y)-47.55%

Tangible BV CAGR (5Y)36.44%

26-Week Price Return-37.15%

Quick Ratio (Annual)2.28x

13-Week Price Return-35.69%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)1.45x

Enterprise Value$51.95M

Asset Turnover (TTM)0.74x

Book Value / Share Growth (5Y)-10.58%

Revenue / Employee (Annual)$468,100

Pretax Margin (Annual)-50.27%

Cash / Share (Annual)$1.75

3-Month Return Std Dev62.49%

Net Income / Employee (TTM)$-410,300

ROE (Last FY)-72.29%

Net Interest Coverage (Annual)-5.87x

EPS Basic Excl Extra (Annual)$-1.68

Receivables Turnover (TTM)3.01x

Total Debt / Equity (Quarterly)0.32x

EPS Incl Extra (TTM)$-1.67

ROI (TTM)-191.23%

P/S Ratio (TTM)2.04x

Pretax Margin (5Y Avg)-586.69%

Revenue / Share (Annual)$3.34

Tangible BV / Share (Annual)$0.97

Price vs S&P 500 (52W)-30.54%

Year-to-Date Return-56.74%

5-Day Price Return-10.35%

EPS Normalized (Annual)$-1.68

ROA (5Y Avg)-72.01%

Net Profit Margin (Annual)-50.27%

Month-to-Date Return-25.03%

Cash Flow / Share (TTM)$-1.08

EBITD / Share (Annual)$-1.24

Operating Margin (Annual)-38.56%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-68.97%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.67

P/TBV (Quarterly)3.76x

P/B Ratio (Annual)3.19x

Inventory Turnover (TTM)1.63x

Pretax Margin (TTM)-102.84%

Book Value / Share (Annual)$1.44

Price vs S&P 500 (13W)-38.37%

Beta1.67x

Revenue / Share (TTM)$1.42

ROE (TTM)-205.58%

52-Week Low$3.28

vGradeC

gGradeC

mGradeC

vgmGradeC

VRCA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.47	-$0.48	-2.86%(-$0.01)
Q4 2025	Mar 11, 2026	-$0.64	-$0.51	+20.31%(+$0.13)
Q3 2025	Nov 14, 2025	-$0.84	$0.13	+115.42%(+$0.97)
Q2 2025	Aug 12, 2025	-$0.83	$0.25	+130.00%(+$1.08)

VRCA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.08

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VRCAVerrica Pharmaceuticals Inc. Common Stock	C	C	C	2.0x	106.2%	85.9%	—	$3.60
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Verrica Pharmaceuticals Inc. Common Stock

Verrica Pharmaceuticals is a dermatology therapeutics company developing novel treatments for contagious viral skin diseases. Its lead product candidate, VP-102, targets molluscum contagiosum and common warts, addressing significant market opportunities in pediatric and adult populations.

VRCA Next Earnings Report

Report dateNov 13, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.52

Revenue estimate$6.41M

Also reporting on Nov 13, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

VRCA Insider Transactions

BuyAug 18, 2026
ROSENBERG NOAH L
Officer
Shares: 6,230Value: $30,610
BuyAug 18, 2026
KIRBY JOHN J.
Chief Financial Officer
Shares: 5,000Value: $24,650
BuyAug 17, 2026
RIEGER JAYSON
Chief Executive Officer
Shares: 25,000Value: $125,750
BuyAug 17, 2026
ZAWITZ DAVID
Chief Operating Officer
Shares: 6,000Value: $29,880

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

CSBRChampions Oncology, Inc.Biological Products
SLSNSolesence, Inc. Common StockCosmetics & Toiletries
CITRCitroTech Inc.Chemicals
ZTEKZentek Ltd. Common StockIndustrial Chemicals
LNZALanzaTech Global, Inc. Common StockIndustrial Chemicals
SAFXXCF Global, Inc. Class A Common StockIndustrial Chemicals
SGMOSangamo Therapeutics, Inc. Common StockBiological Products
WNWMeiwu Technology Company Limited Ordinary SharesSoap & Detergents

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$3.28

High$9.82